Huntington National Bank Sells 344 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Huntington National Bank trimmed its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 5.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,607 shares of the company’s stock after selling 344 shares during the period. Huntington National Bank’s holdings in HCA Healthcare were worth $2,279,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Plato Investment Management Ltd boosted its holdings in shares of HCA Healthcare by 51.6% in the 3rd quarter. Plato Investment Management Ltd now owns 4,770 shares of the company’s stock valued at $1,937,000 after purchasing an additional 1,624 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd boosted its stake in HCA Healthcare by 23.2% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 2,923 shares of the company’s stock valued at $1,188,000 after buying an additional 550 shares in the last quarter. GSA Capital Partners LLP acquired a new position in HCA Healthcare during the third quarter worth about $567,000. Waverton Investment Management Ltd grew its holdings in shares of HCA Healthcare by 12.7% during the 3rd quarter. Waverton Investment Management Ltd now owns 159,382 shares of the company’s stock valued at $64,767,000 after purchasing an additional 17,968 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV acquired a new stake in HCA Healthcare in the third quarter valued at approximately $325,000. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at HCA Healthcare

In related news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael S. Cuffe sold 8,358 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the sale, the executive vice president now directly owns 29,678 shares of the company’s stock, valued at approximately $11,438,494.76. This trade represents a 21.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,155 shares of company stock worth $5,608,990. 1.60% of the stock is owned by corporate insiders.

HCA Healthcare Price Performance

HCA stock opened at $342.96 on Friday. The company’s 50-day moving average is $386.00 and its 200-day moving average is $357.03. HCA Healthcare, Inc. has a 1 year low of $238.82 and a 1 year high of $417.14. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. The stock has a market capitalization of $86.87 billion, a PE ratio of 15.40, a price-to-earnings-growth ratio of 1.34 and a beta of 1.68.

HCA Healthcare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Friday, December 13th. HCA Healthcare’s dividend payout ratio is currently 11.85%.

Analyst Ratings Changes

A number of brokerages have recently commented on HCA. Wells Fargo & Company increased their price target on HCA Healthcare from $395.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Royal Bank of Canada lifted their price target on HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Wolfe Research upgraded shares of HCA Healthcare to a “strong-buy” rating in a research report on Thursday, August 29th. Barclays dropped their price target on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, HCA Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $385.00.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.